DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR
Clinical safety rating: safe
MAOIs can cause hypertensive crisis Can cause insomnia and tachycardia.
Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Pseudoephedrine sulfate is an alpha-adrenergic receptor agonist causing vasoconstriction.
| Metabolism | Desloratadine is metabolized to 3-hydroxydesloratadine via CYP2C8 and CYP3A4. Pseudoephedrine is partially metabolized in the liver by N-demethylation. |
| Excretion | Desloratadine: 41% urine (metabolites), 47% feces (metabolites); pseudoephedrine sulfate: 70-90% renal (unchanged), 1% biliary. |
| Half-life | Desloratadine: 27 hours (terminal); pseudoephedrine sulfate: 5-8 hours (terminal, dependent on urine pH). |
| Protein binding | Desloratadine: 83-87% bound (primarily albumin); pseudoephedrine sulfate: minimal binding, ~20% bound. |
| Volume of Distribution | Desloratadine: ~16.8 L/kg (high Vd, extensive tissue distribution); pseudoephedrine sulfate: ~2.6-3.5 L/kg (moderate Vd). |
| Bioavailability | Desloratadine: 76% (oral); pseudoephedrine sulfate: ~100% (extended-release formulation). |
| Onset of Action | Desloratadine: 1 hour (oral); pseudoephedrine sulfate: 30-60 minutes (oral). |
| Duration of Action | Desloratadine: 24 hours (once-daily dosing); pseudoephedrine sulfate: 24 hours (extended-release formulation). |
| Molecular Weight | Desloratadine: 310.82 Da; Pseudoephedrine sulfate: 428.54 Da (combined molecular weight not applicable as it is a combination product). |
| Action Class | Antihistamine (H1-receptor antagonist) and Sympathomimetic (alpha-adrenergic agonist) |
One tablet (desloratadine 5 mg/pseudoephedrine sulfate 240 mg) orally once daily.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | Contraindicated in GFR < 30 mL/min. For GFR 30-59 mL/min: not recommended due to lack of data. For GFR ≥ 60 mL/min: no adjustment needed. |
| Liver impairment | No specific Child-Pugh based recommendations. Use with caution in severe hepatic impairment; desloratadine clearance reduced. |
| Pediatric use | Not approved for pediatric patients; safety and efficacy not established in children <12 years. For ≥12 years: same as adult. |
| Geriatric use | Use with caution due to increased sensitivity, risk of CNS effects, and potential renal impairment. Consider starting at lower doses; avoid in patients with severe renal impairment. |
| 1st trimester | Limited human data; animal data suggest low risk. Avoid use in first trimester unless benefit outweighs risk. |
| 2nd trimester | Safety has not been established; use only if clearly needed. |
| 3rd trimester | Use near term may cause uterine contractions and decreased placental perfusion due to pseudoephedrine; avoid use in third trimester. |
Clinical note
MAOIs can cause hypertensive crisis Can cause insomnia and tachycardia.
| FDA category | Animal |
| Placental transfer | Pseudoephedrine crosses the placenta; desloratadine likely crosses but data are limited. Both have evidence of placental transfer in animal studies. |
| Breastfeeding |
■ FDA Black Box Warning
None.
| Common Effects | Insomnia |
| Serious Effects | Cardiovascular events (e.g., hypertension, tachycardia, arrhythmias, myocardial infarction, stroke), Seizures, Psychiatric disturbances (e.g., anxiety, hallucinations, paranoia), Urinary retention, Ischemic colitis, Severe allergic reactions (e.g., anaphylaxis, angioedema) |
Hypersensitivity to desloratadine, pseudoephedrine, or any componentSevere hypertensionSevere coronary artery diseaseConcurrent use or within 14 days of MAOIsNarrow-angle glaucomaUrinary retentionSevere renal impairment
| Precautions | Severe hypertension and/or tachycardia, Cardiovascular disease including ischemic heart disease and arrhythmias, Increased intraocular pressure, Diabetes mellitus, Thyroid dysfunction, Prostatic hypertrophy/urinary retention, Renal impairment, Seizure disorders, Use in elderly patients |
| Food/Dietary |
Loading safety data…
| Both desloratadine and pseudoephedrine are excreted into breast milk in small amounts. Pseudoephedrine may cause irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for adverse effects. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Desloratadine: no human data, animal studies show no evidence of harm; risk cannot be excluded. Pseudoephedrine: associated with increased risk of gastroschisis in first trimester; possible uterine vasoconstriction in second/third trimester. Overall, avoid in first trimester; use only if benefit outweighs risk in second/third trimester. |
| Fetal Monitoring | Monitor fetal heart rate and uterine activity with prolonged use due to potential vasoconstriction. Assess blood pressure and heart rate in mother. Fetal ultrasound if used in first trimester to detect gastroschisis. No specific monitoring for desloratadine. |
| Fertility Effects | No known effect on fertility from desloratadine. Pseudoephedrine may temporarily decrease uterine blood flow, but no evidence of lasting fertility impact. |
| Avoid alcohol as it may increase sedative effects. Limit or avoid caffeine-containing foods/drinks (coffee, tea, soda, chocolate) to reduce risk of nervousness, insomnia, and tachycardia. No specific food interactions with desloratadine; pseudoephedrine is not significantly affected by food. |
| Clinical Pearls | Desloratadine is a long-acting antihistamine; pseudoephedrine sulfate is a nasal decongestant. The 24-hour formulation provides extended relief. Use with caution in patients with hypertension, hyperthyroidism, or benign prostatic hyperplasia. Avoid in narrow-angle glaucoma. Monitor for insomnia and nervous system stimulation. May cause dry mouth and urinary retention. |
| Patient Advice | Take one tablet daily with a full glass of water; do not crush or chew. · Avoid taking with other sympathomimetic amines (e.g., pseudoephedrine, phenylephrine) to prevent excessive cardiovascular stimulation. · May cause drowsiness; avoid driving or operating heavy machinery until you know how the medication affects you. · Limit caffeine intake to reduce additive stimulant effects. · Do not use if you have severe hypertension, coronary artery disease, or are taking MAOIs currently or within past 14 days. |